I think you mean announce FDA concluding pre-submission discussions with suggestion RDGL go ahead and submit IDE application for human trials?
RDGL has announced efforts to start human trials for several years now, so that wouldn't be news. To date, RDGL hasn't submitted an IDE application for FDA to consider human trials.
Regarding institutional investors, very few buy stocks under $10 and fewer, if any, buy from otc exchange. More likely scenario would be an established company in this space taking a position after some positive human trial data.